text:
The ECF Board is the Foundation's decision-making body and works closely with the management in overseeing how we work to achieve our goals. The Board decides on the Foundation's finances and overall strategy, supervises its grants policy, and consults with the Advisory Council in defining ECF's priorities.
The Board meets three times a year. It consists of a minimum of five and a maximum of twelve members, including a Treasurer, Chair and Deputy Chair. Both the Chair and the Deputy Chair act as the Foundation's two Vice Presidents. The ECF President is an Extraordinary Member of the Board.
Members of the Board are broadly representative of the wider Europe and of the disciplines and fields of activity related to our goals.
Articles of Association of the European Cultural Foundation.
President - HRH Princess Laurentien of the Netherlands
President of ECF and Extraordinary Member of the Board
Chair - Görgün Taner (TR)
General Director of the Istanbul Foundation for Culture and Arts (IKSV), Turkey
Deputy Chair - Rien van Gendt (NL)
Member of the Board of Rockefeller Philanthropy Advisors, New York
Treasurer - Rob Defares (NL)
Chief Executive Officer, IMC International Marketmakers Combination, The Netherlands
Isabel Alçada (PT), Writer, Counselor to the Presidentof the Republic, former Minister of Education, Portugal
Mária Hlavajová (SK), Artistic Director, BAK, Basis voor actuele kunst, Utrecht, The Netherlands
Nike Jonah (UK), Creative Producer, United Kingdom
Joachim Rogall (DE), Chief Executive Officer, Robert Bosch Stiftung, Germany
Mats Rolén (SE), Associate Professor, Former Research Director, Stiftelsen Riksbankens Jubileumsfond, Sweden
Christophe de Voogd (F), Reader and researcher, Institute of Political Studies, France
Igno van Waesberghe (NL), Advisor representing Prins Bernhard Cultuurfonds, The Netherlands
External Advisers
ECF has a secondary tier of advisers working closely with the Foundation in deciding on grants, programmes and other awards.
Jury for ECF Princess Margriet Award for Culture
The Princess Margriet Award for Culture honours former ECF President, HRH Princess Margriet of the Netherlands, and was initiated by ECF in cooperation with the Dutch Ministry of Education, Culture and Science and the Dutch Ministry of Foreign Affairs.
The five members of the 2017 Jury are:
- Andreas Broeckmann (Curator, Leuphana Arts Program, Lüneburg/Berlin)
- Juan Freire (Founding Partner, Teamlabs and mmodulUS, Madrid)
- Ivan Krastev (Chairman of the Centre for Liberal Strategies, Sofia)
- Ruth Mackenzie (Artistic Leader Holland Festival, Amsterdam)
- Saskia van Stein (Director of Bureau Europa, platform for architecture & design, Maastricht)
Connected Action for the Commons
Connected Action for the Commons is a three year action research programme (2014-2016) led by ECF in collaboration with six partner hubs, working together as a network: Culture 2 Commons - Alliance Operation City, Clubture Network, Right to the City - (Croatia), Les Tetes de l'Art (France), Krytyka Politczyna (Poland), Oberliht (Moldova), Platoniq - Goteo (Spain), and Subtopia (Sweden). Our partnership with the hubs is driven by activities in the areas of the Commons, Public Space, Culture and Economy.
The advisors to the Connected Action for the Commons programme help us to select idea makers to attend the Idea Camp, select recipients of our R&D grants, and give expert input on the development of the programme.
In 2015 the advisors are:
- Rana Zincir Celal, (CY), Programme Manager of Columbia Global Centers, Turkey
- Juan Freire, (ES) Biologist, entrepreneur and professor, Spain
- Rene Kubasek, (CZ) Consultant to various NGO's, former Director, Czech Centre Bucharest, Romania.


text:
With the groundbreaking for the first phase of expanding the Beth Morean Arts Center accomplished, Arts Center officials and friends celebrated with glass maestro Dale Chihuly at a dinner hosted by Drs. Edward Zbella and Lisa Nemec.
The backdrop was a nighttime view of Tampa Bay from the fourth floor of 400 Beach Drive, and Chihuly gave guests a summary of the many projects he is undertaking throughout the world, among them large installations in Dubai, Kuwait, Singapore and Las Vegas.
In St. Petersburg, his sculptures will fill about half the new space, and the permanent collection will be one of a kind.
"I promise you," Chihuly told the group of about 70 guests, "when it comes to your Chihuly collection, I'm going to make you the best project I've ever done."
Arts Center board of trustees chairman Terry Brett recalled a visit to the Seattle area earlier this year to visit Chihuly and other artists. Brett, Arts Center executive director Evelyn Craft, Zbella and St. Petersburg Mayor Rick Baker were in the delegation.
"We were treated like family," Brett said.
Baker, whose trademark greeting is "It's a great day in St. Petersburg," said the city has much to celebrate. "This is not just a museum," he said at the private dinner event. "This is an industry."
And then, having celebrated the Tampa Bay Rays' advancing into the American League Division Series, Baker brought souvenir baseball caps for the artist and every other person attending the event. It was catered by Parkshore Grill.
Beth Ann Morean, who gave the lead gift for the Arts Center expansion, was there. Jimmy Aviram, a developer and longtime acquaintance of Chihuly's who is credited with inspiring the partnership, attended with his wife, Haia. Also in the group were Marshall Rousseau, director of the Chihuly Collection; Dick Jacobs, board chairman emeritus; Tom and Mary James; capital campaign director Katee Tully, with Helen Levine; Lenne Nicklaus-Ball; Barbara Sansone and Terry Collins; Dr. Mary Ann Pittman and Steven Boldt; Mirella and Norman Smith; Karen and Jim Holbrook; and Emily and Dr. Fred Gurtman.
The expanded Arts Center, which also will contain a hot shop for glass artists, is scheduled to open in 2010.

subset: commoncrawl


text: Neurocrine Biosciences Company Profile (NASDAQ:NBIX) Company Profile Analyst Ratings Earnings History Earnings Estimates Dividend History Insider Trade Headlines Social Media Chart About Neurocrine Biosciences (NASDAQ:NBIX) Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems. Industry, Sector and Symbol: Sector: Medical Industry: Bio Therapeutic Drugs Sub-Industry: Biotechnology Symbol: NASDAQ:NBIX CUSIP: 64125C10 Web: www.neurocrine.com Capitalization:Market Cap: $5.19026 billionOutstanding Shares: 88,221,000Average Prices:50 Day Moving Avg: $54.39200 Day Moving Avg: $49.1752 Week Range: $37.35 - $60.00 P/E:Trailing P/E Ratio: N/AForeward P/E Ratio: -31.87P/E Growth: 1.77Sales & Book Value:Annual Revenue: $6.34 millionPrice / Sales: 820.43Book Value: $3.91 per sharePrice / Book: 15.06 Profitability:EBIDTA: ($219,960,000.00)Return on Equity: -69.86%Return on Assets: -48.65%Debt:Debt-to-Equity Ratio: 1.04%Current Ratio: 19.36%Quick Ratio: 19.36%Misc:Average Volume: 877,209 shs.Beta: 0.41Short Ratio: 11.78 Frequently Asked Questions for Neurocrine Biosciences (NASDAQ:NBIX) What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.01. The company had revenue of $6.34 million for the quarter, compared to analysts' expectations of $0.61 million. During the same period in the previous year, the business earned ($0.46) EPS. View Neurocrine Biosciences' Earnings History. Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2017? 17 brokers have issued 12-month price targets for Neurocrine Biosciences' stock. Their predictions range from $55.00 to $100.00. On average, they expect Neurocrine Biosciences' share price to reach $68.25 in the next year. View Analyst Ratings for Neurocrine Biosciences. What are analysts saying about Neurocrine Biosciences stock? Here are some recent quotes from research analysts about Neurocrine Biosciences stock: 1. Cowen and Company analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017) 2. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017) 3. Needham & Company LLC analysts commented, "Company continues to prepare for Ingrezza launch ahead of 4/11/17 PDUFA date. We expect approval based on strength of Phase 3 data, followed by launch ~6wks later. We believe Boxed Warning/ REMS are possible. Phase 2 pediatric Tourette Syndrome (TS) data are expected May 2017 (was Apr). Given efficacy trend observed in adult Phase 2 TS, we believe Ingrezza will likely be active in pediatric TS as well. Elagolix NDA submission for Endometriosis by Abbvie is expected 3Q17 (was 2H17), triggering a $30M payment to Neurocrine. Phase 3 results in Uterine Fibroids are expected by YE17. We believe stock is attractive ahead of near term events. BUY." (2/10/2017) 4. HC Wainwright analysts commented, "We expect FDA to agree in early 2017 that Atara has demonstrated comparability between clinical batches of ATA-129, or EBV-CTL, and the prior material produced at MSKCC, paving the way for Phase 3 start. We believe comparability data will include the number of cells to administer, cytoreactivity, cell storage time, restriction studies (HLA types), variability based on release criteria, and the methods by which data are collected. CMC amendment standard for new clinical material Importantly, a CMC amendment is standard practice for an IND when new clinical material is introduced; therefore, we view Atara's process as normal." (1/18/2017) 5. Jefferies Group LLC analysts commented, "While the study showed a stat sig improvement on the Clinical Global Impression of Change scale (CGI; p=0.015), the study did not reach stat sig on the 1EP of Yale Global Tic Severity Scale (YGTSS; p=0.18). No further trial details were released. Although a setback, we note that this does not directly read through to the pediatric study readout expected in April." (1/18/2017) Who are some of Neurocrine Biosciences' key competitors? Some companies that are related to Neurocrine Biosciences include Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), bluebird bio (BLUE), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Axovant Sciences Ltd (AXON), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO) and Loxo Oncology (LOXO). Who are Neurocrine Biosciences' key executives? Neurocrine Biosciences' management team includes the folowing people: William H. Rastetter Ph.D., Independent Chairman of the BoardDavid-Alexandre C. Gros M.D., President, Interim Chief Financial Officer, Chief Operating OfficerKevin C. Gorman Ph.D., Chief Executive Officer, DirectorEric S. Benevich, Chief Commercial OfficerHaig P. Bozigian Ph.D., Chief Development OfficerKyle Gano Ph.D., Chief Business Development OfficerDimitri E. Grigoriadis Ph.D., Chief Research OfficerMalcolm Lloyd-Smith, Chief Regulatory OfficerChristopher F. O'Brien M.D., Chief Medical OfficerDarin M. Lippoldt, Corporate Secretary Who owns Neurocrine Biosciences stock? Neurocrine Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.86%), Janus Henderson Group PLC (6.08%), BlackRock Inc. (5.45%), PERCEPTIVE ADVISORS LLC (5.30%) and BB Biotech AG (3.91%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences. Who sold Neurocrine Biosciences stock? Who is selling Neurocrine Biosciences stock? Neurocrine Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Sectoral Asset Management Inc, Jennison Associates LLC, Marshall Wace North America L.P., BlackRock Inc., JPMorgan Chase & Co., Emerald Advisers Inc. PA and Capital World Investors. Company insiders that have sold Neurocrine Biosciences stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Dimitri E Grigoriadis, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Timothy P Coughlin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences. Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock? Neurocrine Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, TimesSquare Capital Management LLC, HealthCor Management L.P., FMR LLC, Goldman Sachs Group Inc., Senzar Asset Management LLC, Franklin Resources Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Neurocrine Biosciences. How do I buy Neurocrine Biosciences stock? Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurocrine Biosciences' stock price today? One share of Neurocrine Biosciences stock can currently be purchased for approximately $58.96. MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)Community Ranking: 4.3 out of 5 ( )Outperform Votes: 543 (Vote Outperform)Underperform Votes: 90 (Vote Underperform)Total Votes: 633MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days. Analyst Ratings Consensus Ratings for Neurocrine Biosciences (NASDAQ:NBIX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.Ratings Breakdown: 1 Hold Rating, 16 Buy RatingsConsensus Rating:Buy (Score: 2.94)Consensus Price Target: $68.25 (15.76% upside) Analysts' Ratings History for Neurocrine Biosciences (NASDAQ:NBIX) Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateFirmActionRatingPrice TargetImpact on Share PriceDetails9/21/2017Robert W. BairdReiterated RatingOutperform$66.00High9/17/2017Needham & Company LLCReiterated RatingBuy$58.00Low9/7/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$70.00Low8/24/2017Piper Jaffray CompaniesSet Price TargetBuy$68.00Medium8/9/2017Cowen and CompanyReiterated RatingOutperform$60.00 -> $65.00Medium8/4/2017BMO Capital MarketsBoost Price TargetOutperform$75.00 -> $84.00Low5/30/2017Jefferies Group LLCReiterated RatingBuy$66.00Low5/24/2017J P Morgan Chase & CoSet Price TargetBuy$57.00Medium5/25/2017Leerink SwannLower Price TargetOutperform$68.00 -> $66.00Low5/15/2017Bank of America CorporationReiterated RatingBuy$70.00Medium5/2/2017Barclays PLCBoost Price TargetOverweight$60.00 -> $70.00Low3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/A2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/A2/10/2017ICAPReiterated RatingOutperform$55.00N/A1/27/2017CIBCUpgradeMarket Perform -> OutperformN/A1/19/2017Deutsche Bank AGReiterated RatingBuy$65.00 -> $62.00N/A11/22/2016Citigroup Inc.Initiated CoverageMarket Perform$55.00N/A11/2/2015NomuraBoost Price TargetBuy$34.00 -> $43.00N/A(Data available from 9/26/2015 forward) Earnings Earnings History for Neurocrine Biosciences (NASDAQ:NBIX)Earnings History by Quarter for Neurocrine Biosciences (NASDAQ NBIX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListen5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListen2/14/2017Q416($0.55)($0.51)$4.55 millionViewListen11/2/2016Q316($0.57)($0.43)ViewN/A5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/A2/11/2016Q415($0.32)($0.34)$3.33 millionViewListen10/29/2015Q315($0.25)($0.40)$6.66 millionViewListen7/29/2015Q2($0.29)($0.28)$0.41 millionViewListen4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/A2/9/2015Q414($0.24)($0.26)ViewN/A11/3/2014Q314($0.21)($0.21)ViewN/A8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/A4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/A2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/A10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/A7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListen5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListen2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListen10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/A7/31/2012($0.03)($0.01)ViewN/A5/2/2012($0.01)ViewN/A10/31/2011$0.19$0.56ViewN/A7/28/2011$0.04$0.04ViewN/A5/3/2011$0.05$0.05ViewN/A2/10/2011$0.04$0.05ViewN/A(Data available from 1/1/2011 forward) Estimates Earnings Estimates for Neurocrine Biosciences (NASDAQ:NBIX)2017 EPS Consensus Estimate: ($2.31)QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20174($0.89)($0.54)($0.65)Q2 20174($0.68)($0.61)($0.65)Q3 20174($0.72)($0.28)($0.50)Q4 20174($0.76)($0.28)($0.52)(Data provided by Zacks Investment Research) Dividends Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)No dividend announcements for this company have been tracked by MarketBeat.com Insider Trades Insider Trading and Institutional Ownership History for Neurocrine Biosciences (NASDAQ:NBIX)Insider Ownership Percentage: 4.80%Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00 9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50 8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00 8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00 7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.00 5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00 5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.80 5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.00 5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00 5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97 5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.00 4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30 4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32 2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76 2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51 2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80 2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82 2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.00 2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75 2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.00 1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75 1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50 1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50 1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.50 1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00 11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.00 9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.00 8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.00 8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.00 5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.00 5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00 4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.40 4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00 2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75 2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00 2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00 1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25 1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00 1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50 1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25 1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50 1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50 11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00 11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12 10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00 10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00 9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00 7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00 7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00 7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00 7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00 6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00 6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00 6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00 3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00 3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00 2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00 1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50 1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50 1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50 1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50 1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50 1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00 1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00 1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00 1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00 1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00 12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00 12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00 12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00 12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50 12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90 12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50 12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00 12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00 12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00 11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00 11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39 10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00 10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00 10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50 9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00 1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.00 1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.00 1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50 1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.00 1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.00 1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00 1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.00 9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.00 9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.00 8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.96 8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.75 8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.70 8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.00 8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.35 7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00 6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81 6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00 6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87 (Data available from 1/1/2013 forward) Headlines Headline Trends for Neurocrine Biosciences (NASDAQ:NBIX) Latest Headlines for Neurocrine Biosciences (NASDAQ:NBIX) Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineStocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 91finance.yahoo.com - September 22 at 10:39 AMToday's Research Reports on Stocks to Watch: Neurocrine Biosciences and Biocryst Pharmaceuticalsfinance.yahoo.com - September 22 at 10:39 AMNeurocrine Biosciences, Inc. (NBIX) Receives Outperform Rating from Robert W. Bairdwww.americanbankingnews.com - September 21 at 6:22 PMNeurocrine Biosciences, Inc. (NBIX) Given "Buy" Rating at Needham & Company LLCwww.americanbankingnews.com - September 17 at 8:48 AMNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the ... - PR Newswire (press release)www.prnewswire.com - September 16 at 11:51 PMNeurocrine Announces Data on the Real-World Patient Impact of TD from the RE-KINECT Study to be Presented at the 2017 Annual Psych Congressfinance.yahoo.com - September 16 at 6:52 AMZacks: Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Announce Earnings of -$0.50 Per Sharewww.americanbankingnews.com - September 15 at 12:32 PMEQAL's Underlying Holdings Imply 10% Gain Potentialwww.nasdaq.com - September 14 at 8:08 AMNeurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Analystswww.americanbankingnews.com - September 12 at 4:40 AMInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 26,250 Shares of Stockwww.americanbankingnews.com - September 8 at 4:22 PMChristopher Flint Obrien Sells 52,817 Shares of Neurocrine Biosciences, Inc. (NBIX) Stockwww.americanbankingnews.com - September 7 at 7:20 PMNeurocrine Biosciences' (NBIX) "Buy" Rating Reiterated at Oppenheimer Holdings, Inc.www.americanbankingnews.com - September 7 at 3:26 PMNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conference - PR Newswire (press release)www.prnewswire.com - September 7 at 6:37 AMNeurocrine Biosciences to Present at the Morgan Stanley 15th Annual Global Healthcare Conferencefinance.yahoo.com - September 7 at 6:37 AMNeurocrine Biosciences, Inc. (NBIX) Rating Increased to Hold at ValuEnginewww.americanbankingnews.com - September 2 at 8:50 PMInteresting NBIX Put And Call Options For October 20th - Nasdaqwww.nasdaq.com - August 31 at 7:41 AMStocks To Watch: Neurocrine Biosciences Sees Relative Strength Rating Jump To 82finance.yahoo.com - August 31 at 7:40 AMNeurocrine Biosciences to Present at the Baird 2017 Global Healthcare Conferencefinance.yahoo.com - August 31 at 7:40 AMZacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $24.60 Millionwww.americanbankingnews.com - August 29 at 1:50 AMToday's Research Reports on Trending Tickers: Portola Pharmaceuticals Inc. and Neurocrine Biosciences, Inc.finance.yahoo.com - August 25 at 8:59 AMNeurocrine Biosciences, Inc. (NBIX) PT Set at $68.00 by Piper Jaffray Companieswww.americanbankingnews.com - August 24 at 6:28 PMNeurocrine Biosciences, Inc. (NBIX) Receives Average Rating of "Buy" from Brokerageswww.americanbankingnews.com - August 18 at 4:40 AMNeurocrine Biosciences: Ingrezza's Strong Launch, Pipeline To Create Value - Seeking Alphaseekingalpha.com - August 17 at 8:51 PMSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.finance.yahoo.com - August 15 at 2:45 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Dimitri E. Grigoriadis Sells 15,354 Shareswww.americanbankingnews.com - August 14 at 1:27 PMIHS Markit Score downgrades Neurocrine Biosciences Inc to 12 out of 100, ranking negatively in two out of three available IHS Markit categories.finance.yahoo.com - August 12 at 6:08 AM$24.60 Million in Sales Expected for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) This Quarterwww.americanbankingnews.com - August 11 at 5:56 PMNeurocrine Biosciences Incfinance.yahoo.com - August 11 at 6:46 AMFeatured Company News - Mylan Launches Avonza(TM) in Indiafinance.yahoo.com - August 11 at 6:46 AMIHS Markit Score upgrades Neurocrine Biosciences Inc to 34 out of 100, despite ranking positively in only one IHS Markit category.finance.yahoo.com - August 11 at 6:46 AM-$0.49 Earnings Per Share Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarterwww.americanbankingnews.com - August 9 at 2:12 PMInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 22,500 Shares of Stockwww.americanbankingnews.com - August 8 at 7:44 PMNeurocrine Biosciences, Inc. to Post FY2019 Earnings of $0.13 Per Share, Jefferies Group Forecasts (NASDAQ:NBIX)www.americanbankingnews.com - August 7 at 9:56 AMNeurocrine Biosciences Off To A Good Start With Ingrezza - Seeking Alphaseekingalpha.com - August 6 at 5:58 AMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Announces Quarterly Earnings Resultswww.americanbankingnews.com - August 5 at 8:22 PMEdited Transcript of NBIX earnings conference call or presentation 3-Aug-17 9:00pm GMTfinance.yahoo.com - August 4 at 10:08 PMNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target Raised to $84.00 at BMO Capital Marketswww.americanbankingnews.com - August 4 at 4:16 PMEARNINGS SUMMARY: Details of Neurocrine Biosciences Inc Q2 Earnings Reportwww.rttnews.com - August 4 at 6:12 AMNeurocrine Biosciences Reports Second Quarter 2017 Resultsfinance.yahoo.com - August 4 at 6:12 AMNeurocrine reports 2Q lossfinance.yahoo.com - August 4 at 6:12 AMChristopher Flint Obrien Sells 8,734 Shares of Neurocrine Biosciences, Inc. (NBIX) Stockwww.americanbankingnews.com - July 31 at 7:32 PMNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results - PR Newswire (press release)www.prnewswire.com - July 30 at 7:25 PMNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Resultsfinance.yahoo.com - July 29 at 5:04 AMToday's Research Reports on Stocks to Watch: Neurocrine Biosciences, Inc. and Ionis Pharmaceuticalsfinance.yahoo.com - July 26 at 3:47 AMNeurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Brokerageswww.americanbankingnews.com - July 24 at 10:54 AM$1.56 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarterwww.americanbankingnews.com - July 22 at 10:57 AMNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer - PR Newswire (press release)www.prnewswire.com - July 22 at 6:51 AMNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officerfinance.yahoo.com - July 22 at 6:51 AMNeurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officerfinance.yahoo.com - July 22 at 6:51 AMNeurocrine Poised To Corner Tardive Dyskinesia Market With Ingrezza - Seeking Alphaseekingalpha.com - July 11 at 3:05 AM Social Chart Neurocrine Biosciences (NBIX) Chart for Tuesday, September, 26, 2017 This page was last updated on 9/26/2017 by MarketBeat.com Staff


text:
Getronics becomes Cisco's Gold Partner in Saudi Arabia
Getronics, a provider of Information & Communications Technology (ICT) solutions and services, recently announced that it has become Cisco's sole Gold Partner operating in Saudi Arabia, certified to offer consultancy, support and network integration services.
Getronics was awarded Gold status after a period of assessment by Cisco and independent auditors. Specializing in IP telephony, security, voice and wireless LAN infrastructure, Getronics has been offering network integration, business solutions and managed services in the Middle East since the early 1990s.
The Cisco Gold Partner Certification is one of three levels of certification awarded to Cisco partners. The initial stage, Permier Partner status, is awarded following the attendance of sales and technical training and other minimum requirements. Silver is achieved when a partner has gained expertise in specific Cisco technology and achieved the required level of technical support.
Gold Partners will have achieved expertise in at least three Cisco technology specializations and will have the ability to provide the highest levels of support. Cisco Systems conducts independent audits at the partner site to confirm achievement of all the requirements to achieve gold certification.
Jon Saunders, Unified Channels Manager of Cisco Systems Middle East said: "The Cisco Partner Certification Program was developed to enable customers to select a solution provider with a proven level of skill and expertise."
Getronics' headquarters is in Amsterdam, with regional head offices in Boston, Singapore and Washington DC. It employs 29,000 people in over 30 countries and has five offices covering the Middle East region, based in Saudi Arabia, the United Arab Emirates (UAE) and Bahrain. Getronics' shares are traded on Euronext Amsterdam. Cisco Systems is an international leader in networking for the Internet. — (menareport.com)
© 2002 Mena Report (www.menareport.com)


text:
Egyptian satellite "Nilesat 201" was successfully launched on Wednesday night from a base in South America on board of the "Ariane 5" rocket. The cost of the new satellite amounted to US$237 million and have been financed from Nilesat's own resources as well as a loan from a regional bank.
Egypt's Information Minister Anas el-Feki said the launch of the Egyptian satellite confirms the country's leading media role. According to him, Nilesat 201 supports Egypt's competitive position in this strategic area. Nilesat Company, one of the major television and radio broadcasting service providers, transmits over 560 TV channels and 100 radio stations, the minister noted.
[1] http://www.albawaba.com


text:
Jump to content
Lockheed Martin has the task of delivering 19 million lines of code needed to support Joint Strike Fighter program's F-35 Lightening 11 aircraft, a project that will require 10 years of work by more than 1,000 developers from many companies in nine countries. The project requires a robust process management solution to enable collaboration in the distributed group environment, while keeping the project within exact specifications and meeting International Traffic in Arms Regulations (ITAR).
To meet these challenges, Lockheed Martin deployed Serena Dimensions™. Dimensions enables the JSF team to track and enforce several hundred processes in software development and production change management. Among the biggest benefits Dimensions provides is enforcement of critical processes, saving time and eliminating the costs required for oversight of manual processes. In addition, Dimensions delivers the reporting, auditing, security and ease of use that are essential to Lockheed in supporting their highly distributed developer base.


text:
NetWellness is a global, community service providing quality, unbiased health information from our partner university faculty. NetWellness is commercial-free and does not accept advertising.
Thursday, September 21, 2017
Erectile Dysfunction (ED)
Penis shrinking
I bought a penis enloargement bill and it seems I am getting smaller. Is this possible? If so, how do I find out if this pill was legitimate? It was shipped under MLS labs. Is there anything I can do to increase the size of my penis or the scrotum?
First, stop taking the pill. These pills and their ingredients are not regulated by the government. Next, please see a urologist to discuss your penis and scrotal size.
Allen D Seftel, MD
Formerly, Professor of Urology
School of Medicine
Case Western Reserve University


text:
MotorCity Casino Hotel to Welcome Daughtry, 11/20
MotorCity Casino Hotel welcomes Daughtry to Sound Board on Thursday, November 20, 2014 at 8 p.m.
Fronted by singer, songwriter, and musician Chris Daughtry, the American rock band includes: Josh Paul, Brian Craddock, Josh Steely and Elivio Fernados.
Daughtry has scored four No. 1 hits, garnered four Grammy nominations, won four American Music Awards, sold over 8 million albums, 18 million singles worldwide and sold out concerts around the world. Daughtry's self-titled debut was the fastest selling rock debut in Soundscan history and its follow up Leave This Town marked the quintet's second consecutive No. 1 album and Daughtry's third album Break The Spell was certified gold in four weeks of its release.
Daughtry's single "Waiting For Superman" broke into the top 15 and new single "Battleships'" is racing up the charts. Its latest album Baptized was released in November 2013.
Tickets are ($65, $50 and $45 [GA Standing]) and go on-sale Friday, September 12, 2014 via Ticketmaster. To purchase tickets, please call Ticketmaster at (800) 745-3000 or visit online at www.ticketmaster.com. Tickets are also available through the Sound Board Box Office Saturday and Sunday and on show days**. Guests must be at least 21 years old to attend this performance.
SOUND BOARD, an intimate live performance venue is located at MotorCity Casino Hotel. The venue features four bars and several private suites that are available to create an unforgettable live entertainment event. Free and convenient valet and self-parking are available.
Visit http://www.soundboarddetroit.com/ for more information about tickets, hotel packages, and Sound Board. Get in touch with us at 866-STAY-MCC or firstname.lastname@example.com.


text:
Pre-Eid Egyptian stocks see a boost over IMF visit
The Egyptian stock market see a pre-Eid boost on positive news on the IMF visit
Follow >
Click here to add Arabeya Online Securities as an alert
Disable alert for Arabeya Online Securities,
Click here to add Ashraf Abdel-Aziz as an alert
Disable alert for Ashraf Abdel-Aziz,
Click here to add Cairo as an alert
Disable alert for Cairo,
Click here to add EGX30 as an alert
Disable alert for EGX30,
Click here to add International Bank as an alert
Disable alert for International Bank,
Click here to add International Monetary Fund as an alert
Disable alert for International Monetary Fund,
Click here to add National Societe Generale Bank as an alert
Disable alert for National Societe Generale Bank
Egyptian stocks leapt back into the green on Wednesday in the last trading session before the Eid Al-Adha holiday, encouraged by an impending visit from the International Monetary Fund.
The benchmark EGX30 climbed 1.63 per cent to close out the week at 5,793 points, more than making up for the previous day's losses.
"News about the IMF visit encouraged investors after a recent relative slowdown," Ashraf Abdel-Aziz, head of institutions sales at Arabeya Online Securities, told Ahram Online.
An IMF delegation is due to arrive in Cairo on Monday for a visit that may finalise a long-awaited $4.8 billion loan many experts believe is needed to shore up Egypt's economy.
From the 178 stocks traded on Wednesday, 139 gained in value and 20 declined.
Turnover climbed too, after a recent dip, reaching some LE585.9 million ($96m). But it remains significantly lower than the six-month record is reached in September.
"Investors are watching to see what will come up," Abdel-Aziz said.
Orascom Telecom Media and Technology led the market in terms of turnover, gaining 5 per cent. Commercial International Bank was close behind, its shares climbing 2 per cent.
Fellow blue chips Telecom Egypt and National Societe Generale Bank (NSGB) gained 2.3 and 1.2 per cent, respectively.
The broader-based EGX70, charting the performance of lower-cap stocks favoured by Egyptian investors, gained around 1.8 per cent.
Egyptians and non-Arab foreigners were net-buyers to the tune of LE7.5 million and LE12 million respectively. Other Arabs sold LE19.5 million more in stocks than they bought.
Top Headlines
- Al Tayer bucks the US department store trend with Bloomingdale's Kuwait opening
- Gulf Islamic banks set to outperform conventional banks for second year: Moody's
- Jordan secures EU finance for socioeconomic and environmental programs
- Same-day service deliveries in GCC an untapped market: Wing CEO
- Will terror attacks damper Arabs' appetite for European holidays?
- Morsi's US visit boosts Egypt's stock markets
- Palestine Securities Exchange closes busy trading week ahead of Eid Al-Adha holiday
- Iraq strife could trigger higher oil prices - IMF's Lagarde
- Euro Zone Consumer Prices to Shrink for Second Month, Boosting Deflation Risk (Euro Open)
- Morsi on thin ice with IMF deal


text:
Remember the Backstreet Boys' Collaboration With Shania Twain?
Subscribe to Taste of Country on
There wasn't an album or a single, or even an official music video. But for one night, the Backstreet Boys sang country, and it was actually really good!
Nick, Kevin, Brian, A.J. and Howie joined Shania Twain for a performance of her hit song 'From This Moment' at a show in Miami. The CBS special aired in 1999 and ended up on Twain's 'The Specials' DVD package.
Oft-forgotten Howie Dorough begins singing lead with Twain before the others take a turn. The country singer sparkles in a flowing silver gown, while the six men (boys?) are clad in the best '90s fashion — that means pleated black pants and long black jackets.
BSB also performed 'All I Have to Give' with the singer during the Miami special. 'From This Moment' was written with Twain's parents in mind.


text:
The wife of Royals pitcher Wade Davis left a ticket to Game 1 as a tip for her waiter. He called it the "best tip ever," but that was yesterday. Today he probably wishes she had just left some cash.
Former Tennessee Titans DB Wade Davis Discusses Being Gay In The NFL
The Wade Davis story has been making the rounds recently and it is an interesting one. Ten years ago he was struggling to earn a spot with the Tennessee Titans while also keeping up appearances in the Tennessee locker room. In an interview with Outsports, discussing his time with the Titans and teammates Jevon Kearse…


text: I don't see a place to submit patches. Is there a patch manager for numpy? Here's a patch to defer importing 'tempfile' until needed. I previously mentioned one other place that didn't need tempfile. With this there is no 'import tempfile' during 'import numpy' This improves startup by about 7% --- numpy/lib/_datasource.py (revision 5576) +++ numpy/lib/_datasource.py (working copy) @@ -35,7 +35,6 @@ __docformat__ = "restructuredtext en" import os -import tempfile from shutil import rmtree from urlparse import urlparse @@ -131,6 +130,7 @@ self._destpath = os.path.abspath(destpath) self._istmpdest = False else: + import tempfile self._destpath = tempfile.mkdtemp() self._istmpdest = True Andrew email@example.com


text:
To commemorate the 150th anniversary of the Civil War (2011-2015), the Tennessee State Library and Archives is sending teams of archivists and conservators to communities across Tennessee.
Individuals may schedule an appointment, and we will digitally copy and assist in the preservation of your Civil War era manuscripts, artifacts and photographs.
Digital copies of these items, representing the rich Civil War heritage of Tennessee families, will become part of a virtual exhibit commemorating the 150th anniversary of the war in Tennessee.
Log in to leave a comment. Sign In / Sign Up


text:
ball powder?
View Single Post
December 3, 2012, 12:47 PM
Mike Irwin
Join Date: April 13, 2000
Location: Northern Virginia
Posts: 39,097
Can I visit your universe in which Unique is cleaner than a ball powder?
I never found Unique to be particularly clean burning, especially not more so than WW 231, which is my go-to powder for just about all of my handgun loading.
But Unique is cleaner than Red Dot...
"How in the world would a revolver know what kind of powder you used?"
Obviously, the revolver, being a nonsentient lump of steel wouldn't know, but every type of powder has a distinct set of characteristics that are unique to that powder, and to a degree, that type.
For example, double-base powders, because of the nitroglycerine content, generally burn a lot hotter than single base powders.
A lot can depend on how quickly the pressure rises, and how long that rise lasts.
Some of the worst powders for frame cutting are those with a quick pressure rise but a fairly long pressure pulse.
"The gift which I am sending you is called a dog, and is in fact the most precious and valuable possession of mankind" -Theodorus Gaza
Baby Jesus cries when the fat redneck doesn't have military-grade firepower.
Mike Irwin
View Public Profile
Find More Posts by Mike Irwin
Page generated in
seconds with


text:
Member since 12/18/2013
- 1 total post
- 1 question
Questions from Mellych22
Cost of brow bone reduction? Is there any places near Dallas Texas? (photo)
I've done some research and I'm not finding any places near me who do this procedure . I would be willing to travel . READ MORE


text:
Can Macbook air 13" work with sony a77/24mpx raw photo and video?
In my netbook i can import my raw and read them ,but if i zoom a raw into lightroom , netbook take 10-15sec for rendering it .
Are these the old a700 (12 megapixel) RAWs, or the new a77 (24 megapixel) RAWs? How long does it take to do the same RAW conversions on your Vaio?
Performance isn't always exactly the same for Mac and PC applications, but if you have some idea of how fast things run on a laptop with a 2.4 GHz dual-core Core i5 ("intel i5 520m") and a regular hard drive, that might give you some idea of how fast they would run on another laptop with similar hardware.
Thx friend.
When i spoken about raw's test , i used only the a77 raws.
I made another test after your hint . I imported the sames photos into lightroom at minimal rendering (No 1:1) and after i zoomed them in the library.
The results are :
1 is the sony Vaio with i5 520m ,8 gb ram 533mhz (I read this with cpuz) and nvidia 330m
2 Is the netbook (Yesterday i installated ssd) with 4 gb ram and c60 with ati shared
4 Is my desktop with 3770k intel ,16gb ram and nvidia 660gtx
They have installed ssd and last version of windows 8 and lightroom .
Now i know that with a laptop is impossible arrive at 5 seconds for a 1:1 rendering ,but i want arrive near the sony vaio's time.
Now can you give me your opinion or do the same test with macbook ?
This is an original raw A77's Raw (This is my first linked photo from dropbox,so tell me if it doesn't work)
|Post (hide subjects)
|Posted by
|Jan 4, 2013
|Jan 5, 2013
|Jan 5, 2013
|Jan 5, 2013
|Jan 8, 2013
|Jan 9, 2013
|Jan 10, 2013
|Bald Eagle by anisah
from Features - lips/mouth
|heron and fish by APenza
from A Big Year - birds
|Cows Cowering Under Rare California Super Cell by RBFresno
from -The Old Cows-


text: On Sun, Feb 15, 2009 at 9:04 AM, Gael Varoquaux <email@example.com> wrote: > Hi all, > > Sorry for the multiple posting, this concerns various groups, and I'd > rather the information not be lost. > > While working on getting our in-lab library ready to be merged with NiPy, > I ran into some sort of 'sphinx extension mess' where various sphinx > extension would have side effects on each other, and most important, the > extensions did not work with sphinx trunk. > > I got the side effects to be limited by cleaning up the generated code > from autosummary before each run: I added the following code in my > sphinx conf.py: > > ################################################################################ > # Hack: run the autosummary generation script > import shutil > if os.path.exists('generated'): > shutil.rmtree('generated') > os.system('%s sphinxext/autosummary_generate.py -o generated *.rst' % > sys.executable) > ################################################################################ > > I am attaching a diff of all the modifications I made to get the various > extensions to work. I hope you can use it to get your various extensions > working on sphinx trunk quicker. For the NiPy guys, I will be committing > these changes in the fff2 tree soon, and we can go over this at the > sprint. > > This does raise a problem: this extension code is all over the place, in > various repository. Some of the code cannot live in the sphinx repo, as > it introduces dependencies. However, as the extensions are not importable > from Python (I can't do 'from matplotlib.sphinxext import mathmpl'), the > different projects using them end up copying them in their repo, and thus > there are several versions floating around not updated. Some of the > extensions would do not add externa dependencies to sphinx. These should > be pushed into sphinx, with tests. That way as sphinx evolves, they do > not break. > > Gaël > In my setup the plot directive doesn't create any graphs, it always skips plots with the following warning WARNING: C:\Josef\_progs\building\scipy\scipy-trunk-new-r5551\doc\source\tutoria l\stats.rst:300: (ERROR/3) Error in "plot" directive: no content permitted. When debugging this, I discovered that in plot_directive.py it creates the `class plot_directive(Directive)` which doesn't seem to work. If I use the same function as in the other path of the try except, then graphs are correctly created. I don't know if this is specific to my version combination or if this is a bug. >>> import docutils >>> docutils.__version__ '0.5' >>> import sphinx >>> sphinx.__version__ '0.5' >>> Josef -------------------------------- plot_directive.py starting line 417 ---------- try: from docutils.parsers.rst import Directive except ImportError: from docutils.parsers.rst.directives import _directives def plot_directive(name, arguments, options, content, lineno, content_offset, block_text, state, state_machine): return run(arguments, content, options, state_machine, state, lineno) plot_directive.__doc__ = __doc__ else: print 'running plot_directive class' #this class doesn't do anything ## class plot_directive(Directive): ## def run(self): ## return run(self.arguments, self.content, self.options, ## self.state_machine, self.state, self.lineno) #copied from above def plot_directive(name, arguments, options, content, lineno, content_offset, block_text, state, state_machine): return run(arguments, content, options, state_machine, state, lineno) plot_directive.__doc__ = __doc__


text:
It's June 17th and Texas Just Got a New Law Protecting the Phrase "Merry Christmas"
We've heard of "Christmas creep," where Christmas stuff starts happening earlier and earlier in the year. And we've heard of the WAR on Christmas. But this is the first time we've dealt with 'War on Christmas' creep.
On Thursday, Rick Perry, the governor of Texas, signed a law that protects schools from being sued for using the phrase "Merry Christmas."
Right now is pretty much EXACTLY as far away from Christmas as you can be. We're just a week away from being halfway between last Christmas and next Christmas.
Under the bill, schools can use the phrase "Merry Christmas." They can put up Christmas decorations, sing Christmas carols, pass out candy canes, and do any other Christmas-related activities.
BUT…they also have to give SOME representation to other religions. So, you know, expect schools all over Texas to have one token Menorah or a poster explaining Ramadan on display somewhere amidst wall-to-wall Christmas stuff.
Perry says, quote, "I realize it's only June, but I'm glad that we're standing up for religious freedom in this state. Religious freedom does not mean freedom FROM religion."


text:
Service providers are well-positioned to capitalize on the migration by call centers from on-premises platforms to a virtual, hosted call center service that provides an advanced set of call center functionality, the benefits of a hosted architecture (centralized queuing and routing, remote agents, enhanced availability options) and a lower total cost of ownership.
BroadSoft has announced Call Center Xpress, a bundled call center solution that enables telecommunications service providers to deliver a feature-rich, end-to-end and fully scalable hosted call center solution to enterprise customers. Call Center Xpress is designed to help service providers offer hosted call centers to a broad range of customers, delivering the benefits of a hosted architecture to enterprise customers in a simple-to-deploy package.
BroadSoft Call Center Xpress leverages call center capabilities from three market-leading providers: BroadSoft, which delivers unified communications (UC) services, automatic call distribution (ACD) and call routing, supervisor and agent client interfaces and reporting through its BroadWorks platform; Inference Solutions, which provides advanced interactive voice response (IVR) services; and CTI Group, which offers robust call recording and quality management functionality.
"Call Center Xpress extends features and functionality typically reserved for large enterprise call centers -- such as voice-enabled IVR services, speech analytics, advanced call center functionality, and unified communications services -- to small businesses and mid-market enterprises," said David Bukovsky, vice president products, BroadSoft, in a statement. "As a result, service providers can quickly capitalize on the migration by customers from on-premise platforms to virtual call center infrastructure with an offering that we believe meets current call center needs and introduces new capabilities that can enhance customer experiences and operational efficiency."
BroadSoft Call Center Xpress is ideally suited for all call center environments, delivering the benefits of a hosted architecture, such as network-based queuing, geographically dispersed agents and a pay-for-use model.
"Businesses of all sizes see tremendous benefit in being able to purchase a broad suite of hosted communications services from a single, trusted provider," said James Turner, CEO, Inference Solutions. "By partnering with BroadSoft on the Call Center Xpress solution, we allow service providers to deliver and capitalize on this market opportunity -- addressing new high revenue call center markets, particularly in the small business and mid-market categories."
Key benefits of Call Center Xpress include an abundance of features, a lower total cost of ownership (TCO) than on-premises call center solutions, carrier-friendly, scalable, on-demand and standards-based interfaces that the open Xtended Application Programming Interface (API) enable integration with additional third-party applications.
"Historically, enterprise customers seeking to access such a broad range of advanced call center features would have to cobble together products from multiple vendors, at multiple premises, with the ensuing high cost of ownership," said John Birbeck, CEO, CTI Group. "We're thrilled to expand our partnership with BroadSoft as part of Call Center Xpress, because it is designed to allow service providers to offer an affordable, advanced, bundled package to business customers of all sizes and geographic dispositions."
BroadSoft's Call Center Xpress delivers an end-to-end solution that meets all the functional needs of a typical call center, along with the resources to help a service provider bring their offer to market.


text:
Luxury on
wheels – the MINI Paceman brings swathes of style, total luxury and a healthy
dose of practicality to your everyday drives.
Inside, MINI has made sure the Paceman feels premium with its minimalist dashboard layout giving it a clear feel. In the back, there are two seats which have been chosen by MINI for their plush vibe. Each passenger has their own seat, and there's a central panel with cup holders which makes the experience like business class on an airline. Up front, your driver's seat has been positioned so that you're in command with a broad view ahead. Every seat is sports-inspired in its shape and cushioning to enhance the ride.
Agile and powerful
The option of an all-wheel drive makes the Paceman a versatile option for every driver. Choose one of these versions if you want an ultra-sporty drive that's responsive and agile, no matter what the weather, or road.
Its engines range from 112bhp in the Cooper D through to 218bhp in the John Cooper Works edition. Along with the John Cooper Works edition, the Cooper S is a sportier choice with its 190bhp engine that can hit 0-60mph speeds of approximately seven seconds. If you're keen to go for a model that cuts your running costs, opt for the Cooper D, which can return up to 67mpg, and has CO2 emissions of just 111g/km.
The Paceman has a number of features that help to keep you safe on the road. There's dynamic stability control, which prevents you from swerving while you drive, and the ALL4 versions have traction control to minimise skidding. Parking distance controls are another standard feature that help to keep your Paceman in showroom condition.
Every Paceman comes with DAB digital radio, Bluetooth connectivity and air conditioning so you can relax on every journey. Optional upgrades include sat nav, a Harman Kardon hi-fi system and MINI Connected – a system that allows you to use apps on a compatible smartphone.
See the luxury for yourself with a test drive from Marshall in the north-east and south of England. To book a time, simply use the online tool or give us a call to chat to one of the team.
01202 065081
01256 442651
01722 622122
01472 728491


text:
Adopting me when I was an infant and loving me as much as they could.
my friend helped me through anerexia and saved me from being hit my a car, twice. im extremly clumsy lol
I was going through some rough times and my little brother found a little cross pendant on the ground and he gave it to me saying that it would protect me. Haven't left it off since :-))
Yeah i know he's really cute lol. What the nicest thing someone has done for you ? ( if you care to share lol )
LOL - Will do. Yeah its always nice to know someone cares about you. If you have any problems please don't hesitate to contact me lol :-))
when my classmate helped me find a scholarship. I did not even ask her to do it for me, but she did, and I'm really thankful for that.
When a friend of mine gave me $500- I didn't even ask for it nor did I have to pay it back, but it was right on time because I was broke at that moment (he had won that money from scratching a lottery ticket)
Thank you! :-))
committed my wife to the funny farm.
my parents gave me a warm place to live, and loved me even though I was adopted when I was born. :)
thanks :)
Being there for me and a best friend too me when I didnt trust or have anyone else.
Sent me some great coffee, chocolates and a perfumed sock.
Related Questions
prettytasty 31-35, F 14 Answers 3 Nov 18, 2010
sweetparis101 22-25, F 11 Answers 9 Jun 18, 2011
Oblivioustothepain 18-21, F 10 Answers 4 Oct 31, 2011
LazzyFox 41-45, F 8 Answers 5 Jan 12, 2012
scubafever 46-50, M 5 Answers 1 Jan 13, 2012
I've gotten a couple compliments today, but the only one i can remember is, "I like your hair." Probably because i hate my hair, and i dont do anything with it because im boring :D...IntenseCookie 18-21, F 26 Answers 8 Jul 26, 2012
shaneromanova 22-25, M 15 Answers 3 Aug 2, 2012 in Dating & Relationships
toxiiclullaby 18-21, F 8 Answers 3 Nov 19, 2012 in Community
AERogers92 18-21, F 10 Answers 4 Dec 11, 2012 in EP


text:
Jane 'Gean' Porter
b.1731 Orange County, Virginia
d.1814 Augusta County, Virginia
Family tree▼
m. Bef. 1730
m. 1749
Facts and Events
Source:Morton, 1920:522 provides a child list of for William Porter, probably based on Transcript:Will of WilliamPorter, Rockbridge CountyVA, 1780|Williams will of 1780]]. That list excludes child Jane. User:RBH has pointed out that this exclusion is in error, as daughter Jane Black is clearly identified in his will. User:RBH suggests that this error probably arose from a misreadng of the will, with Morton mistaking a reference to daughter "Gean" for a reference for wife "Gean". The full text of the will makes it clear that he had a daughter Gean (e.g., Jane) who married a Black.
User:RBH identifies Jane's husband as Samuel Black. Her comment was:
Samuel Black always called her Rebecca and says that in his will. He also says she was born in 1731 but that could have been a transcribing error. They were married in 1749. Also stated in Sam'l.Black's will. This information was taken from " The Family History of William Porter Jr. of Rockbridge County, Virginia 1740-1804" Mary E. Porter.
While there's no doubt, based on the transcription of William's will, that William's daughter Jane married a "Black", additional evidence would be needed to show that her husband was Samuel Black. The fact that Samuel Black's will identifies his wife as "Rebecca" would seem to contradict the idea that his wife was Jean Porter, and requires explanation. Perhaps Rebecca was his second wife, or perhaps Jane married a different Black. Additional data needed.
Given that this source apparently has her marring at Age 12, I think its very unlikely that Jane Porter's name was "Rebecca Jane" Also, the early use of a dual name "Rebecca Jane" seems unlikely. More likely, data about two separate persons has been conflated. Q 13:03, 28 August 2013 (EDT)
RBH says: Rebecca Jane Porter Black was born in 1731 and the 1737 date is in error. This would make her age 18 at her marriage date of 1749. Please see your own page of we relate concerning the family of Andrew Alexander and Katherine Thompson. It has the same information that I have as to Jane Porter and Samuel Black. Jane Alexander married John Black s/o Samuel and Jane Porter Black.


text:
Bobby Valentine's decision to pinch hit Daniel Nava for Jose Iglesias raised many questions on Sunday, and they're still coming on Monday.
Pete Abraham spoke to Tom Caron about that at-bat on Red Sox Gameday Live, saying it was the first question asked of the Red Sox manager when the team arrived in Tampa. Valentine says that Iglesias would be fine moving forward.
Abraham thinks that Valentine's decision to pinch-hit Nava shows that the manager is still dedicated to winning this season.
To hear everything that Abraham had to say on the matter, check out the above video.
Powered by WordPress.com VIP


text:
Addiction by Design:
"Natasha Schull's Addiction By Design is fascinating, absorbing, and at times, a bit frightening. . . . Schull's work will have wide relevance to many audiences, including those interested in technology studies, media studies, software studies, game studies, values-in-design, and the psychology and sociology of addiction and other technologically mediated behavioral disorders."--Hansen Hsu, Social Studies of Science
"Original, ambitious, and written with elegant lucidity, Addiction by Design presents us with a narrative that is as compulsive as the behavior it describes. The book repositions debates in the field of gambling and will surely become a classic text in studies of society and technology."--Gerda Reith, American Journal of Sociology
"Based on fifteen years of ethnographic work, Addiction by Design is an ambitious and thought-provoking book that challenges the neoliberal ethos currently governing the way in which governments and professionals think about gambling addiction."--Kah-Wee Lee, Technology and Culture
"A handbook on regaining our proper orientation to the world. Schüll's book offers a grim warning about the ways others can deliberately cut us off from natural and supernatural joys."--Leah Libresco, Commonweal
"A stunning portrayal of technology and the inner life. Searing, sobering, compelling: this is important, first-rate, accessible scholarship that should galvanize public conversation."--Sherry Turkle, Massachusetts Institute of Technology, author of Alone Together: Why We Expect More from Technology and Less from Each Other
"A fascinating, frightening window into the world of gambling in Las Vegas and the technological innovations that deliberately enhance and sustain the 'zone'--the odd, absorbed state for which extreme machine gamblers yearn. An astute and provocative look at addiction and its complex moral, social, and emotional entanglements."--T. M. Luhrmann, Stanford University
"At the heart of Schüll's book is the interplay between the players and the machine; between the players and the machine manufacturers; between the players and the math program; and between the players and the 'zone' that the machines help produce. A tour de force that changes the dialogue on gambling addiction."--Henry Lesieur, author of The Chase: Career of the Compulsive Gambler
"Schüll's clear and dramatic writing style is itself addictive. One is drawn into the ways in which the interactions among the different stakeholders lead to players' experience of being drawn into a 'zone' where they remain until all resources are gone. This is a must-read narrative that points to the many variants of screen addiction possible today."--Don Ihde, author of Bodies in Technology
"This gripping, insightful, and poignant analysis of machine gambling offers a kind of object lesson in the intensified forms of consumption that computer-based technologies enable. An exemplary case of the way in which close, critical investigation of specific sites of capitalism can provide a deeper understanding of both intimate experience and widespread socioeconomic arrangements."--Lucy A. Suchman, author of Human-Machine Reconfigurations
"Schüll offers a provocative and important study of the imperative some people feel to lose themselves in a machine. The ethnography is rich and deep, shedding original light on the significance of addiction and gambling in American culture. The story told in the book is absolutely riveting."--Emily Martin, author of Bipolar Expeditions
File created: 4/21/2017
Questions and comments to: firstname.lastname@example.com
|New Book E-mails
|New In Print
|PUP Blog
|Princeton APPS
|Sample Chapters
|Princeton Legacy Library
|Exam/Desk Copy
|Recent Awards
|Princeton Shorts
|Freshman Reading
|PUP Europe
|About Us
|Contact Us
|PUP Home


text:
Next generation operating system reportedly to be first announced at BUILD conference in April.
Microsoft is abandoning the Windows 8 line completely and will skip right to Windows 9 with the next version, according to a report from Winsupersite's Paul Thurrott.
Thurrott writes that Windows 9, codenamed "Threshold" will look more like Windows 7 than the previous iteration of Winodws, with Microsoft likely removing some of the least popular features of the troubled OS. On PC editions of the OS Microsoft will likely downplay Metro, while offer a redesigned Metro on mobile editions of the platform.
From Thurrott:
But Threshold is more important than any specific updates. Windows 8 is tanking harder than Microsoft is comfortable discussing in public, and the latest release, Windows 8.1, which is a substantial and free upgrade with major improvements over the original release, is in use on less than 25 million PCs at the moment. That's a disaster, and Threshold needs to strike a better balance between meeting the needs of over a billion traditional PC users while enticing users to adopt this new Windows on new types of personal computing devices.
The expected announcement date of April 2014, at the BUILD conference, will be just weeks after Microsoft completes a massive reorganization of itself. With this reorganization Microsoft hopes to be a more lean and efficient machine, more nimble to market changes. Windows Vista and 8 were both victims of a lethargic "too big to fail" Microsoft. This company wouldn't cut it in a computing environment where Android, not just Mac, is a viable competitor to Windows, so it will be interesting to watch what a reorganized Microsoft does with as it crosses the threshold with this new version of Windows.
Source: Winsupersite


text:
Join the RAC and get breakdown cover from £34.99. We fix 4 out of 5 vehicles at the roadside!
Up to 65% off RAC Car Insurance with 9+ years no claims discount.
Up to 65% off with 9+ years no claims discount.
Get prepped for your trip abroad with our European Driving Kits, Sat Navs and Travel Essentials.
Buying a car? Don't be duped - check the history first with the UK's most comprehensive car check. Selling a car? Give your buyers confidence with our seller's report.
Don't worry, buy replacement batteries online with same day fitting by our patrols.
Read our guide to driving in Europe and find out all the information you need, including country specific advice.
Packed with the best car reviews, drives, expert motoring advice, news from the RAC and so much more…
There are driving eyesight requirements that all motorists must meet by law. You can and should wear glasses or contact lenses in order to fulfil the criteria. If you're caught driving without the correct standards of vision for driving, you could be prosecuted.
Road crashes caused by poor driver vision are estimated to cause 2,900 casualties and cost £33 million per year in the UK. Eyesight deterioration can be slow which is why it's so important to have your eyes tested at least every two years, or straight away if you notice a problem.
If you have any problems with your eyes other than being long or short sighted or colour-blind, you must inform the DVLA. If you're unsure whether you need to report your eye ailment, use the A to Z of medical conditions on the DVLA website.
You must be able to read (with glasses or contact lenses, if necessary) a car number plate made after 1 September 2001 from 20 metres. You must also have a visual acuity of at least decimal 0.5 (6/12) measured on the Snellen scale and an adequate field of vision. Your optician will be able to test for all three of these factors.
Drivers aged over 70 have to declare when renewing their licence that their eyesight meets minimum legal standards. They don't have to provide evidence of this but could be held liable if they're in an accident and it's thought that poor eye health was a contributing factor.
Every learner driver is subjected to a quick eye test at the beginning of their official driving test. This involves correctly reading a number plate on a parked vehicle. If they get it wrong, they fail the entire test immediately. Also, the DVLA will be told and your licence will be revoked. You can reapply for a driving license but you'll be asked to have an eyesight test with DVSA at a driving test centre. If you pass, you can then go on to take the driving test.
Find further information here on car insurance or speak to one of our RAC advisers on 0330 159 1019 to get a quote.
Get up to 65% off RAC Car Insurance with 9+ years no claims discount